SiteOne Therapeutics, Inc.的动态

We’re pleased to share positive Phase 1 clinical results for STC-004, our lead NaV1.8 inhibitor in development for the non-opioid treatment of pain. Key findings: ? Well-tolerated across all dose levels tested, with favorable safety profile ? Pharmacokinetics data support once-daily dosing ? Strong evidence of target engagement and analgesic potential in an experimental pain model “These compelling phase 1 results reinforce the potential of STC-004 as a transformative, non-opioid solution for pain management,” said @John Mulcahy, Ph.D., CEO of SiteOne Therapeutics. “With these results in hand, we are focused on rapidly advancing STC-004 into Phase 2 trials in the second half of this year.” Read the press release here: https://lnkd.in/gcFFKZcM #nonopioidtherapies #painmanagement #pain #drugdiscovery #ionchannels #biotech